• Explore /
  • Poster
  • / Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).

Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).

Abstract Poster

Authors

Keunchil Park

Keunchil Park

Division of Hematology & Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Keunchil Park , Jong-Seok Lee , Ki Hyeong Lee , Joo-Hang Kim , Young Joo Min , Jae Yong Cho , Ji-Youn Han , Bong-Seog Kim , Jin-Soo Kim , Dae Ho Lee , Jin Hyoung Kang , Eun Kyung Cho , In-Jin Jang , Jina Jung , Hyo-Yeon Kim , Hui Jung Sin , Jeewoong Son , Jong Soo Woo , Dong-Wan Kim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01588145

Citation

J Clin Oncol 33, 2015 (suppl; abstr 8084)

DOI

10.1200/jco.2015.33.15_suppl.8084

Abstract #

8084

Poster Bd #

408

Abstract Disclosures

Similar Posters

First Author: Jianchun Duan

First Author: Elaine Shum

First Author: Qing Zhou

First Author: Yi-Long Wu